CTLA4 and hepatocellular carcinoma: Combination therapy durvalumab, IgG1κ mAb for PD-L1, and tremelimumab, anti-CTLA-4 mAb, as a first-line therapy significantly improved OS compared to sorafenib for patients with unresectable HCC [25].